Safety and immunogenicity study of multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-16

  Jaoko, Walter ^a   Karita, Etienne ^b   Kayitenkore, Kayitesi ^b,h   Omosa Manyonyi, Gloria ^a   Allen, Susan ^c   Than, Soe ^d,i   Adams, Elizabeth M ^e   Graham, Barney S ^e   Koup, Richard A ^e   Bailer, Robert T ^e   Smith, Carol ^f   Dally, Len ^f   Farah, Bashir ^a   Anzala, Omu ^a   Muvunyi, Claude M ^b,j   Bizimana, Jean ^b   Tarragona Fiol, Tony ^g   Bergin, Philip J ^g   Ho, Peter Hayes Martin ^g   Loughran, Kelley ^f,k   Komaroff, Wendy ^f   Stevens, Gwynneth ^d   Thomson, Helen ^d   Boaz, Mark J ^d,l   Cox, Josephine H ^d   Schmidt, Claudia ^d   Gilmour, Jill ^g   Nabel, Gary J ^e   Fast, Patricia ^d   Bwayo, Job ^a   more..

^a Kenya AIDS Vaccine Initiative   (Kenya)

^b Projet San Francisco   (Rwanda)

^c EMORY UNIVERSITY   (United States)

^d INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f EMMES CORPORATION   (United States)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h WORLD HEALTH ORGANIZATION   (Switzerland)

ⁱ PFIZER INC   (United States)

^j UNIVERSITY OF RWANDA   (Rwanda)

^k CENTER FOR DEVICES AND RADIOLOGICAL HEALTH   (United States)

^l SANOFI PASTEUR   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; POL PROTEIN; RECOMBINANT REPLICATION DEFECTIVE ADENOVIRUS TYPE 5 VECTOR VACCINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ANTIBODY;

ABNORMAL LABORATORY RESULT; ADULT; AFRICA; ARTHRALGIA; ARTICLE; BLISTER; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEMALE; FLU LIKE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE PAIN; INJECTION SITE REACTION; LEUKOPENIA; MALAISE; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PAPULE; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER; VOMITING; ADENOVIRUS; ADOLESCENT; CLASSIFICATION; DRUG TOXICITY; GENE VECTOR; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; MIDDLE AGED; VIROLOGY;

HUMAN ADENOVIRUS TYPE 5; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADENOVIRIDAE; ADOLESCENT; ADULT; AIDS VACCINES; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; DRUG TOXICITY; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; MALE; MIDDLE AGED; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; YOUNG ADULT;

EID: 77958498605     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0012873     Document Type: Article

References (31)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
2. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194: 1638-1649.
3. Catanzaro AT, Roederer M, Koup RA, Bailer RT, Enama ME, et al. (2007) Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 25: 4085-4092.
4. Eller MA, Eller LA, Opollo MS, Ouma BJ, Oballah PO, et al. (2007) Induction of HIV-specific functional immune responses by a multiclade HIV-1 DNA vaccine candidate in healthy Ugandans. Vaccine 25: 7737-7742.
5. Graham B, Koup R, Roederer M, Bailer R, Enama M, et al. (2006) Phase I Safety and Immunogenicity Evaluation of a Multiclade HIV-1 Candidate DNA Vaccine. J Infect Dis 194: 1650-1660.
6. Koup RA, Roederer M, Lamoreaux L, Fischer J, Novik L, et al. (2010) Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses. PLoS ONE 5: e9015.
7. Tavel JA, Martin JE, Kelly GG, Enama ME, Shen JM, et al. (2007) Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J Acquir Immune Defic Syndr 44: 601-605.
8. Kibuuka H, Kimutai R, Maboko L, Sawe F, Schunk MS, et al. (2010) A Phase I/II Study of a Multiclade HIV-1 DNA Plasmid Prime and Recombinant Adenovirus-type 5 Boost Vaccine in HIV Uninfected East Africans (RV 172). J Infect Dis 201: 600-7.
9. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
10. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, et al. (2008) HIV- 1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
11. Stiles T, Grant V, Mawbey T (2003) Good Clinical Laboratory Practice (GCLP). A quality system for laboratories that undertake the analysis of samples from clinical trials. Ipswich (UK): British Association of Research Quality Assurance. pp 1-17. ISBN 1-904610-00-5.
12. Sprangers MC, Lakhai W, Koudstaal W, Verhoeven M, Koel BF, et al. (2003) Quantifying Adenovirus-Neutralizing Antibodies by Luciferase Transgene Detection: Addressing Preexisting Immunity to Vaccine and Gene Therapy Vectors. J Clin Microbiol 41: 5046-5052.
13. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, et al. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271.
14. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. PNAS 100: 4144-9.
15. Boaz MJ, Hayes P, Tarragona T, Seamons L, Cooper A, et al. (2008) Measuring T-cell immunity in HIV vaccine clinical trials: PBMC and ELISPOT assay proficiency concordance in laboratories from 3 continents. Clin Vaccine Immunol 16: 147-155.
16. Goonetilleke N, Moore S, Dally L, Winstone N, Cebere I, et al. (2006) Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8+ T-Cell Epitopes. J Virol 80: 4717-4728.
17. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, et al. (2007) Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity. Vaccine 25: 2120-2127.
18. Currier J, Kuta E, Turk E, Earhart L, Loomis-Price L, et al. (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260: 157-172.
19. Mwau M, McMichael A, Hanke T (2002) Design and validation of an enzymelinked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18: 611-618.
20. Fauce SR, Yang OO, Effros RB (2007) Autologous CD4/CD8 co-culture assay: A physiologically-relevant composite measure of CD8(+) T lymphocyte function in HIV-infected persons. J Immunol Methods 327: 75-81.
21. Spentzou A, Bergin P, Dilbinder G, Cheeseman H, Ashraf A, et al. (2010) Viral Inhibition Assay: A CD8 T-cell neutralization assay for use in clinical trials of Human Immunodeficiency Virus-1 vaccine candidates. J Infect Dis 201: 720-729.
22. Cox KS, Clair JH, Prokop MT, Sykes KJ, Dubey SA, et al. (2008) DNAgag/ Ad5gag and Ad5gag/Ad5gag Vaccines Induce Distinct T cell Response Profiles. Journal of Virology: J Virol 82: 8161-71.
23. Chen H, Piechocka-Trocha A, Miura T, Brockman MA, Julg BD, et al. (2009) Differential neutralization of HIV replication in autologous CD4 T cells by HIV-specific CTL. J Virol 83: 3138-3149.
24. Julg B, Williams KL, Reddy S, Bishop K, Qi Y, Carrington M, Goulder PJ, Ndung'u T, Walker BD. Enhanced anti-HIV functional activity associated with Gag-specific CD8 T-cell responses. 2010 March 24, 2010:JVI.02031-09.
25. Khurana S, Needham J, Mathieson B, Rodriguez-Chavez IR, Catanzaro AT, et al. (2006) Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J Virol 80: 2092-2099.
26. Karita E, Kayitenkore K, Bayingana R, Sebahungu F, Bizimana J, et al. (2009) Use of HIV rapid tests for assessment of persistence of vaccine-induced antibodies among HIV vaccine recipients. Retrovirology 6(Suppl 3): 97.
27. Sumida SM, Truitt DM, Lemckert AA, Vogels R, Custers JH, et al. (2005) Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein. http://www.ncbi.nlm.nih.gov/ pubmed?term= %22Addo%20MM%22%5BAuthor%5DJ Immunol. 2005 Jun 1; 174(11): 7179-85.
28. Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, et al. (2009) International epidemiology of human pre-existing adenovirus (Ad) type-5, type- 6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine 28: 950-957.
29. D'Souza MP, Frahm N (8203) Adenovirus 5 serotype vector-specific immunity and HIV-1 infection: a tale of T cells and antibodies. Aids 2010 Mar 27 24(6): 803-9. PMCD:20168203.
30. Abbink P, Lemckert AAC, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative Seroprevalence and Immunogenicity of Six Rare Serotype Recombinant Adenovirus Vaccine Vectors from Subgroups B and D. J Virol 81: 4654-4663.
31. Letvin N (2009) Moving Forward in HIV Vaccine Development. Science 326: 1196-1198.